The present invention belongs to the field of pharmaceutical chemistry, and relates to a class of morpholine tyrosine kinase inhibitors, particularly to a class of compounds having Bruton's tyrosine kinase (BTK) inhibition activity, or pharmaceutically acceptable salts, isomers, solvates, crystals or prodrugs thereof, and applications of pharmaceutical compositions containing the compounds and the compounds or compositions in drug preparation. The compounds of the present invention provide good BTK inhibition activity compared to Ibrutinib.